OMP-21M18

DRUG2 trials

Sponsors

OncoMed Pharmaceuticals, Inc.

Conditions

Colorectal CancerSolid Tumors

Phase 1

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

CompletedNCT00744562

OncoMed Pharmaceuticals, Inc.Solid Tumors

Start: 2008-08-31End: 2012-01-31Updated: 2020-09-10

A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

CompletedNCT01189942

OncoMed Pharmaceuticals, Inc.Colorectal Cancer

Start: 2010-09-30End: 2011-02-28Updated: 2020-09-09